Overview
Nydia De La Cruz practices practicing medicine in Koeln, Germany.
Ms. De La Cruz is highly rated in 1 condition, according to our data. Her clinical expertise encompasses Oral Herpes, Cholera, and Atopic Dermatitis.
She is actively involved in clinical research, co-authoring 9 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Nydia C. De La Cruz
Is Nydia C. De La Cruz a top-rated expert for Oral Herpes?
MediFind is an objective health platform that identifies experts based on real-world data. Nydia C. De La Cruz is classified as an Advanced expert for Oral Herpes, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Nydia C. De La Cruz participate in research or clinical trials?
Yes. Nydia C. De La Cruz has published 9 articles and abstracts on conditions like Oral Herpes. You can view a list of Nydia C. De La Cruz's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- Oral HerpesMs. De La Cruz isAdvanced. Learn about Oral Herpes.
- Experienced
- Atopic DermatitisMs. De La Cruz isExperienced. Learn about Atopic Dermatitis.
- CholeraMs. De La Cruz isExperienced. Learn about Cholera.